

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Charles R Thomas, Jr.

eRA COMMONS USER NAME (credential, e.g., agency login): THOMASCH

POSITION TITLE: Professor and Chief

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Dartmouth College, Hanover, New Hampshire	BA	1979	Biology/Education
University of Illinois, Chicago, Illinois	MD	1985	Medicine
Baylor College of Medicine, Houston, Texas	Intern	1986	Internal Medicine
Baylor College of Medicine, Houston, Texas	Residency	1988	Internal Medicine
Rush Medical College, Chicago, Illinois	Fellowship	1991	Medical Oncology
University of Washington, Seattle, Washington	Fellowship	1994	Radiobiology
University of Washington, Seattle, Washington	Residency	1997	Radiation Oncology

A. Personal Statement

I have been a full-time academic clinician and in fall 2021, I began my current role of Professor and Chair of the Dept. of Radiation Oncology & Applied Sciences at Dartmouth-Hitchcock Health and the Geisel School of Medicine at Dartmouth. Previously, I served as the Chair of the Department of Radiation Medicine at a NCI Designated Cancer Center, the Knight Cancer Institute of the Oregon Health & Science University. My special focus is on radiation oncology, thoracic & GI cancers. My clinical and translational research involves studying the interactions between novel systemic therapeutics and ionizing radiation. Additional clinical research interests include the design and execution of translational research-based, combined modality therapeutic clinical trials involving GI and thoracic cancers.

In have been directly involved in the design, execution, and reporting of cancer clinical trials. I have been active in SWOG, NRG/RTOG, ACOSOG.

My health services research interests involve the development of pipeline strategies to increase the pipeline of highly-qualified investigators from under-represented minority groups into radiologic sciences and cancer medicine. I also have an interest in patient-provider communication; burnout assessment and management in academic leaders; and the interaction of mentoring and academic productivity. As such, I am active in sustained mentorship, promoting the careers of promising physician-scientists and lead my department's efforts in mentorship and sponsorship. I am the senior editor of the textbook, *Career Development in Academic Radiation Oncology* (Springer, 2021, ISBN 978-3-030-71854-1 & ISBN 978-3-030-71855-8 (eBook)). I have been recognized by my peers as a recipient of the inaugural Mentor Award by the American society of Radiation Oncology (ASTRO). I'm board certified in medical oncology, internal medicine, & radiation oncology.

Ongoing and recently completed projects include:

NCT03278626
closed

Thomas, Charles (PI)

Title: *Phase I/II Open Label Multi-Center Study of Immune Checkpoint Therapy with Nivolumab for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (S16-00971)*

1R01CA203193-01

Wisnivesky/Slatore (PI)

Role: Co-Investigator

03/01/2016 – 02/28/2021

Title: *Comparative Effectiveness of Limited Resection vs. SBRT for Early Stage Lung Cancer*

RSD1625

Mitin/Herzig/Rana/Tsikitis (PI)

Role: Co-Investigator

07/01/2016 – 12/31/2020

Title: *Response to Neoadjuvant Therapy in Rectal Adenocarcinoma*

B. Positions, Scientific Appointments, and Honors

Positions and Scientific Appointments

2024 (July 1) Chair (Founding), Dept. of Radiation Oncology & Applied Sciences, Geisel School of Medicine @ Dartmouth, Dartmouth-Hitchcock Health

2024 (July 1) Member, Council of Chairs, Geisel School of Medicine & Dartmouth-Hitchcock Health

2024 (July 1) Dean's Academic Board, Geisel School of Medicine @ Dartmouth

2021-present Member, Executive Committee, Dartmouth Cancer Center

2-21-present Member, Clinical Cancer Research Committee (CCRC), Dartmouth Cancer Center

2021-2024 Professor & Section Chief, Radiation Oncology, Dartmouth-Hitchcock Health, Geisel School of Medicine at Dartmouth

2006-2021 Courtesy (Adjunct) Member, Department of Nuclear Engineering & Radiation Health Physics, Oregon State University, Corvallis, OR

2005-2021 Professor & Chairman, Department of Radiation Medicine, Oregon Health & Science University, Portland, OR

2005-2021 Physician-in-Chief, Radiation Oncology Services, Oregon Health & Science University, Portland, OR

2005-2021 Member, Clinical Executive Group, Oregon Health & Science University Knight Cancer Institute, Portland, OR

2005-2021 Member, Graduate Faculty, School of Medicine, Oregon Health & Science University, Portland, OR

Honors

2007 Fellow, American Society of Clinical Oncology (FASCO)

2007 Alpha Omega Alpha

2004 American Association for Cancer Research Special Minority Scholar Award

C. Contribution to Science

I have published over 350 peer-reviewed articles and my contributions involve:

1) I have published several manuscripts in cancer treatment including clinical trials, patient care, and preclinical research.

- a) Chen EY, Kardosh A, Nabavizadeh N, Foster B, Mayo SC, Billingsley KG, Gilbert EW, Lanciault C, Grossberg A, Bensch KG, Maynard E, Anderson EC, Shepard BC, **Thomas CR Jr.**, Lopez CD, Vaccaro GM, OHSU Gastrointestinal Cancer Disease Group: Phase 2 study of preoperative chemotherapy with nab-paclitaxel ad gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. *Cancer Med* 12(12):12986-12995, 2023

- b) Rosch JG, Landry MR, **Thomas CR, Jr.**, Sun C (2019). Enhancing chemoradiation of colorectal cancer through targeted delivery of raltitrexed by hyaluronic acid coated nanoparticles. *Nanoscale* 11(29):13947-13960. *PMCID: PMC7213297*
- c) DuRoss AN, Neufeld MJ, Rana S, **Thomas CR, Jr.**, Sun C (2019). Integrating nanomedicine into clinical radiotherapy regimens. *Adv Drug Deliv Rev* 144:35-56. *PMCID: PMC6745263*
- d) McGinnis GJ, Friedman D, Young KH, Torres ER, **Thomas CR, Jr.**, Gough MJ, Raber J (2017). Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. *Oncotarget* 8(6):9155-9173. *PMCID: PMC5354722*
- e) Zindler JD, **Thomas CR, Jr.**, Hahn SM, Hoffmann AL, Troost EG, Lambin P (2016). Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. *J Natl Cancer Inst* 108(2).

2) **Design and execution of prospective cancer clinical trials.** I have served as PI or Co-PI of multiple national trials. I have also taught in the AACR/ASCO Vail and Flims Methods in Clinical Cancer Research (MCCR) Workshops and currently serve on the Steering Committee of the RSNA Clinical Trials Methodology Workshop (CTMW).

- a) Ludmir EB, **Thomas CR Jr.** (Guest Editors), *Advances in Clinical Trial Design, Execution, & Implementation, Seminars in Radiation Oncology* 33(4):349-438, 2023
- b) Florez MA, Jaoude JA, atel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, **Thomas CR Jr.**, Ludmir EB: Incidence of primary end point changes among active cancer phase 3 randomized clinical trials. *JAMA Netw Open* 6(5):e2313819, 2023
- c) DuRoss AN, Phan J, Lazar A, Walker JM, Guimaraes AR, Baas C, Krishnan S, Thomas CR Jr., Sun C, Bagley AF: Radiotherapy reimaged: Integrating nanomedicines into radiotherapy clinical trials. *Wiley Interdisc Rev Nanomed Nanobiotechnol* 15(3):e1867, 2023
- d) Wozniak AJ, Moon J, **Thomas CR, Jr.**, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR (2015). A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. *Clin Lung Cancer* 16(5):340-347. *PMCID: PMC4497941*
- e) Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, 3rd, **Thomas CR, Jr.**, Mayer RJ, Haddock MG, Rich TA, Willett CG (2013). Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. *Int J Radiat Oncol Biol Phys* 87(4):638-645. *PMCID: PMC3938865*
- f) Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, 3rd, **Thomas CR, Jr.**, Mayer RJ, Haddock MG, Rich TA, Willett CG (2012). Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol* 30(35):4344-4351. *PMCID: PMC3515768*
- g) Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, **Thomas CR, Jr.**, Mayer RJ, Haddock MG, Rich TA, Willett C (2008). Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 299(16):1914-1921.

3) **Barrier assessment, mentorship, and & sponsorship activities for under-represented in medicine investigators pipeline in academic medicine.** I have sponsored multiple URiM investigators to present research seminars at OHSU over the past decade, and I have co-authored multiple publications on the diversity and pipeline issue in medicine.

- a. **Thomas CR Jr.:** CRT Maxims for the Department Chair role in Inclusiveness in Academic Radiation Oncology. *Int J Radiat Oncol Biol Phys* 116(2):229-231, 2023
- b. Baniel CC, Ponce SB, Lichter KE, Peters GW, Small C, Seldon C, Nguyen KT, Khan AF, **Thomas CR Jr.**, Small W Jr., Kahn JM, Olivier KR, Masters AH, Barry PN, Pollom EL, Jaggi R: Society for Women in Radiation Oncology consensus statement on family and medical leave, *Int J Radiat Oncol Biol Phys* 116(2):270-275, 2023

- c. Corrigan KL, Rooney MK, Kouzy R, Manzar G, **Thomas CR Jr.**, Ludmir EB: Selection and prejudice: Addressing clinical trial disparities with a review of current shortcomings and future directions. *Semin Radiat Oncol* 33(4):367-373, 2023
- d. Doll KM, **Thomas CR, Jr.** (2020). Structural Solutions for the Rarest of the Rare - Underrepresented-Minority Faculty in Medical Subspecialties. *N Engl J Med* 383(3):283-285.
- e. Deville C, Jr., Cruickshank I, Jr., Chapman CH, Hwang WT, Wyse R, Ahmed AA, Winkfield KM, **Thomas CR, Jr.**, Gibbs IC (2020). I Can't Breathe: The Continued Disproportionate Exclusion of Black Physicians in the United States Radiation Oncology Workforce. *Int J Radiat Oncol Biol Phys* 108(4):856-863. *PMCID: PMC7354371*
- f. Vapiwala N, **Thomas CR, Jr.**, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD, Jr., Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN (2019). Enhancing Career Paths for Tomorrow's Radiation Oncologists. *Int J Radiat Oncol Biol Phys* 105(1):52-63. *PMCID: PMC7084166*
- g. Thompson RF, Fuller CD, Berman AT, Aneja S, **Thomas CR, Jr.** (2019). Career Enrichment Opportunities at the Scientific Frontier in Radiation Oncology. *JCO Clin Cancer Inform* 3:1-4. *PMCID: PMC6582958*

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=thomas+cr+jr>